Clinical study to investigate the long-term safety and efficacy of human cell line recombinant Factor VIII (human-cl rhFVIII) in previously treated patients with severe haemophilia A

http://isrctn.org/> ◽

10.1186/isrctn90038418 ◽

2013 ◽

Author(s):

Martina Jansen

Keyword(s):

Clinical Study ◽

Factor Viii ◽

Human Cell ◽

Human Cell Line ◽

Haemophilia A ◽

Severe Haemophilia ◽

Safety And Efficacy ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight ® ) in previously treated patients with severe haemophilia A: interim results of the guardian ™ 2 extension trial

Haemophilia ◽

10.1111/hae.12737 ◽

2015 ◽

Vol 21 (5) ◽

Cited By ~ 8

Author(s):

M. Ozelo ◽

M. Misgav ◽

F. Abdul Karim ◽

S. R. Lentz ◽

M. Martin‐Salces ◽

...

Keyword(s):

Haemophilia A ◽

Severe Haemophilia ◽

Safety And Efficacy ◽

Bleeding Prophylaxis ◽

Previously Treated Patients ◽

Previously Treated ◽

The Guardian ◽

Extension Trial

Download Full-text

Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A

Haemophilia ◽

10.1111/hae.14052 ◽

2020 ◽

Vol 26 (4) ◽

Author(s):

Pratima Chowdary ◽

Eric S. Mullins ◽

Barbara A. Konkle ◽

Catherine McGuinn ◽

Young Shil Park ◽

...

Keyword(s):

Haemophilia A ◽

Severe Haemophilia ◽

Open Label ◽

Safety And Efficacy ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A

British Journal of Clinical Pharmacology ◽

10.1111/bcp.13858 ◽

2019 ◽

Vol 85 (4) ◽

pp. 771-781 ◽

Cited By ~ 3

Author(s):

Xavier Delavenne ◽

Yesim Dargaud ◽

Edouard Ollier ◽

Claude Négrier

Keyword(s):

Factor Viii ◽

Cell Line ◽

Human Cell ◽

Sampling Strategy ◽

Human Cell Line ◽

Recombinant Factor Viii ◽

Limited Sampling Strategy ◽

Haemophilia A ◽

Severe Haemophilia ◽

Limited Sampling

Download Full-text

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

Haemophilia ◽

10.1111/hae.13963 ◽

2020 ◽

Vol 26 (3) ◽

Cited By ~ 2

Author(s):

Elena Santagostino ◽

Gili Kenet ◽

Kathelijn Fischer ◽

Tina Biss ◽

Sanjay Ahuja ◽

...

Keyword(s):

Factor Viii ◽

Recombinant Factor Viii ◽

Haemophilia A ◽

Severe Haemophilia ◽

Safety And Efficacy ◽

Previously Treated

Download Full-text

Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China

Haemophilia ◽

10.1111/j.1365-2516.2007.01472.x ◽

2007 ◽

Vol 13 (4) ◽

pp. 351-356 ◽

Cited By ~ 16

Author(s):

J. SHI ◽

Y. ZHAO ◽

J. WU ◽

J. SUN ◽

L. WANG ◽

...

Keyword(s):

Factor Viii ◽

Recombinant Factor Viii ◽

Haemophilia A ◽

Safety And Efficacy ◽

Previously Treated Patients ◽

Previously Treated ◽

Viii Product

Download Full-text

Clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII in previously treated patients with severe haemophilia A

http://isrctn.org/> ◽

10.1186/isrctn87293301 ◽

2013 ◽

Author(s):

Martina Jansen

Keyword(s):

Clinical Study ◽

Haemophilia A ◽

Severe Haemophilia ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text

Observational study of efficacy and safety of human cell line–derived recombinant factor VIII in Canadian adults with moderately severe and severe haemophilia A

Haemophilia ◽

10.1111/hae.14310 ◽

2021 ◽

Author(s):

Haowei (Linda) Sun ◽

Aziz Jiwajee ◽

Jerry Teitel ◽

Michelle Sholzberg

Keyword(s):

Observational Study ◽

Factor Viii ◽

Cell Line ◽

Human Cell ◽

Human Cell Line ◽

Recombinant Factor Viii ◽

Haemophilia A ◽

Severe Haemophilia ◽

Efficacy And Safety

Download Full-text

Clinical study in which the long term effect of Human-cl rhFVIII is investigated in children with severe haemophilia A, who were previously treated in the GENA-03 study

http://isrctn.org/> ◽

10.1186/isrctn99606748 ◽

2013 ◽

Author(s):

Raina Liesner

Keyword(s):

Clinical Study ◽

Term Effect ◽

Haemophilia A ◽

Severe Haemophilia ◽

Long Term Effect ◽

Previously Treated

Download Full-text

Novel, human cell line‐derived recombinant factor VIII (Human‐cl rh FVIII , Nuwiq ® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

Haemophilia ◽

10.1111/hae.12797 ◽

2015 ◽

Vol 22 (2) ◽

pp. 232-239 ◽

Cited By ~ 26

Author(s):

A. Klukowska ◽

T. Szczepański ◽

V. Vdovin ◽

S. Knaub ◽

M. Jansen ◽

...

Keyword(s):

Factor Viii ◽

Cell Line ◽

Human Cell ◽

Human Cell Line ◽

Recombinant Factor Viii ◽

Haemophilia A ◽

Severe Haemophilia

Download Full-text

Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate HaemoctinR SDH in previously treated patients with severe haemophilia A

Haemophilia ◽

10.1111/j.1365-2516.2004.00947.x ◽

2004 ◽

Vol 10 (5) ◽

pp. 438-448 ◽

Cited By ~ 12

Author(s):

D. M. Wolf ◽

R. Rokicka-Milewska ◽

S. Lopaciuk ◽

A. B. Skotnicki ◽

A. Klukowska ◽

...

Keyword(s):

Factor Viii ◽

Clinical Efficacy ◽

Haemophilia A ◽

Severe Haemophilia ◽

Pharmacokinetic Properties ◽

Previously Treated Patients ◽

Previously Treated

Download Full-text